Benzinga | Aug 17, 2021 11:02AM EDT

Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models

* Lixte Biotechnology Holdings Inc (NASDAQ:LIXT) has announced additional results from preclinical studies of its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor.

* Data showed to reduce behavioral sensitization underlying addiction to methamphetamine.

* Related: A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100.

* Behavioral sensitization is widely considered a critical neurobiological mechanism in drug addiction.

* Studies in animal models have shown that dysregulation in the activity of PP2A could be a factor in diseases of the central nervous system, including drug addiction.

* Last month, Lixte commented on LB-100's PP2A inhibition as a potential therapeutic strategy for triple-negative breast cancer.

* The announcement was followed by a report that LB-100, combined with another investigational agent, stimulated bone growth in models of dwarfism.

* Price Action: LIXT shares are down 0.46% at $2.16 during the market session on the last check Tuesday.